Factsheet FY/2016

COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 230,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

<table>
<thead>
<tr>
<th>€ in millions</th>
<th>FY/2016</th>
<th>Change</th>
<th>FY/2015</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales Earnings</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales</td>
<td>29,083</td>
<td>5%</td>
<td>27,626</td>
<td>19%</td>
</tr>
<tr>
<td>EBIT</td>
<td>4,327</td>
<td>9%</td>
<td>3,958</td>
<td>25%</td>
</tr>
<tr>
<td>Net income</td>
<td>1,593</td>
<td>12%</td>
<td>1,423</td>
<td>31%</td>
</tr>
<tr>
<td>Earnings per ord. share in €</td>
<td>2.92</td>
<td>12%</td>
<td>2.61</td>
<td>30%</td>
</tr>
<tr>
<td>Balance sheet and cash flow</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total assets</td>
<td>46,447</td>
<td>8%</td>
<td>42,959</td>
<td>8%</td>
</tr>
<tr>
<td>Non-current assets</td>
<td>34,648</td>
<td>7%</td>
<td>32,480</td>
<td>9%</td>
</tr>
<tr>
<td>Equity</td>
<td>20,420</td>
<td>13%</td>
<td>18,003</td>
<td>16%</td>
</tr>
<tr>
<td>Equity ratio</td>
<td>44%</td>
<td>--</td>
<td>42%</td>
<td>--</td>
</tr>
<tr>
<td>Net debt/EBITDA</td>
<td>2.34</td>
<td>--</td>
<td>2.68</td>
<td>--</td>
</tr>
<tr>
<td>Investments</td>
<td>2,547</td>
<td>26%</td>
<td>2,029</td>
<td>47%</td>
</tr>
<tr>
<td>Operating cash flow</td>
<td>3,574</td>
<td>7%</td>
<td>3,327</td>
<td>29%</td>
</tr>
<tr>
<td>Operating cash flow in % of sales</td>
<td>12.3%</td>
<td>--</td>
<td>12.0%</td>
<td>--</td>
</tr>
<tr>
<td>Profitability</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBIT margin</td>
<td>14.9%</td>
<td>--</td>
<td>14.3%</td>
<td>--</td>
</tr>
<tr>
<td>Return on equity after taxes (ROE)</td>
<td>12.7%</td>
<td>--</td>
<td>13.0%</td>
<td>--</td>
</tr>
<tr>
<td>Return on operating assets (ROOA)</td>
<td>10.1%</td>
<td>--</td>
<td>10.1%</td>
<td>--</td>
</tr>
<tr>
<td>Return on invested capital (ROIC)</td>
<td>8.5%</td>
<td>--</td>
<td>8.3%</td>
<td>--</td>
</tr>
<tr>
<td>Employees (December, 31)</td>
<td>232,873</td>
<td>5%</td>
<td>222,305</td>
<td>3%</td>
</tr>
</tbody>
</table>

1 2015 before special items
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA
3 Including noncontrolling interest
4 2016 pro forma acquisitions; 2015 before special items
5 As LTM average exchange rates for both net debt and EBITDA
6 Investments in property, plant and equipment, and intangible assets, acquisitions

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

SALES BY REGION

- Europe 38%
- Asia-Pacific 10%
- Latin America and Others 5%
- North America 47%

2016: €29.1 billion

SALES BY BUSINESS SEGMENT

- Fresenius Medical Care 56%
- Fresenius Vamed 4%
- Fresenius Kabi 20%
- Fresenius Helios 20%

2016: €29.1 billion

FRESENIUS

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

- Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. As of December 31, 2016, Fresenius Medical Care was treating 308,471 patients in 3,624 dialysis clinics.
- Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
- Fresenius Helios is Europe’s largest private hospital operator. In Germany, HELIOS operates 112 hospitals, thereof 88 acute care clinics (including seven maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal) and 24 post-acute care clinics. Through Quirónsalud, Fresenius Helios operates 43 hospitals, 39 outpatient centers and around 300 Occupational Risk Prevention (ORP) centers in Spain.
- Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

Factsheet FY 2016 © Fresenius SE & Co. KGaA – Investor Relations
FRESENIUS SHARE / ADR

Securities code no. ISIN Ticker symbol ADR CUSIP ADR Ticker symbol Number of shares (December 31, 2016) Market capitalization (December 31, 2016)
578 560 DE0005785604 FRE 35804M105 FSNUY 547,208,371 €40.6 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX

DAX Fresenius share

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX

DAX Fresenius share

SHARE PERFORMANCE ¹

4th quarter 1 year 3 years 5 years 10 years
+4.6% +12.6% +99.6% +211.7% +340.5%

¹ Effective date/closing price: December 31, 2016

DEVELOPMENT SHARE DIVIDENDS IN €

0.22 0.23 0.25 0.29 0.32 0.37 0.42 0.44 0.55 0.62

¹ Proposal

FINANCIAL CALENDAR

Dates
Report on 1st quarter 2017 May 3, 2017
Annual General Meeting, Frankfurt/Main May 12, 2017
Report on 2nd quarter 2017 August 1, 2017
Report on 3rd quarter 2017 November 2, 2017

Please note that these dates could be subject to modifications.

GROUP OUTLOOK 2017

| Targets 2017 ¹ | Sales, growth (in constant currency) | 15% – 17% |
| | Net income ², growth (in constant currency) | 17% – 20% |
| | Capital expenditure | ~6% of group sales |

¹ According to IFRS
² Net income attributable to shareholders of Fresenius SE & Co. KGaA

For the outlook of the business segments please see the Investor News of February 22, 2017.

CONTACT

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
Markus Georgi
Senior Vice President
Telephone: ++49 61 72 6 08-24 85
Investor Relations
Telefax: ++49 61 72 6 08-24 88

Follow us on twitter and linkedin

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11852
Chairman of the Supervisory Board: Dr. Gerd Krick
General Partner: Fresenius Management SE
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg, HRB 11673
Management Board: Stephan Smirnus (Chairman), Mats Henriksson, Dr. Francesco De Mee, Dr. Jürgen Getze, Rice Powell, Dr. Ernst Wastler
Chairman of the Supervisory Board: Dr. Gerd Krick

Factsheet FY 2016 © Fresenius SE & Co. KGaA – Investor Relations